Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lexaria Bioscience (LEXX) Gross Margin (2017 - 2025)

Historic Gross Margin for Lexaria Bioscience (LEXX) over the last 12 years, with Q3 2025 value amounting to 100.0%.

  • Lexaria Bioscience's Gross Margin changed 0.0% to 100.0% in Q3 2025 from the same period last year, while for Nov 2025 it was 100.0%, marking a year-over-year increase of 5500.0%. This contributed to the annual value of 99.61% for FY2025, which is 6500.0% up from last year.
  • As of Q3 2025, Lexaria Bioscience's Gross Margin stood at 100.0%, which was down 0.0% from 100.0% recorded in Q2 2025.
  • In the past 5 years, Lexaria Bioscience's Gross Margin ranged from a high of 100.0% in Q3 2023 and a low of 59.87% during Q4 2021
  • In the last 5 years, Lexaria Bioscience's Gross Margin had a median value of 91.02% in 2023 and averaged 88.11%.
  • Over the last 5 years, Lexaria Bioscience's Gross Margin had its largest YoY gain of 1388300bps in 2021, and its largest YoY loss of -183200bps in 2021.
  • Lexaria Bioscience's Gross Margin (Quarter) stood at 59.87% in 2021, then surged by 40bps to 83.84% in 2022, then grew by 15bps to 96.81% in 2023, then increased by 2bps to 98.52% in 2024, then increased by 2bps to 100.0% in 2025.
  • Its last three reported values are 100.0% in Q3 2025, 100.0% for Q2 2025, and 100.0% during Q1 2025.